What is HC Wainwright’s Forecast for Assertio Q4 Earnings?

Assertio Holdings, Inc. (NASDAQ:ASRT) – Equities research analysts at HC Wainwright boosted their Q4 2026 earnings estimates for Assertio in a research note issued to investors on Monday, January 5th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $1.22 per share for the quarter, up from their prior forecast of $1.20. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Assertio’s current full-year earnings is ($0.15) per share.

ASRT has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Assertio in a report on Wednesday, October 8th. Zacks Research raised Assertio from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 30th. Finally, Wall Street Zen raised shares of Assertio to a “buy” rating in a research note on Saturday, November 22nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $30.63.

Assertio Trading Up 5.4%

Assertio stock opened at $9.63 on Tuesday. The stock has a 50-day moving average price of $11.10 and a 200 day moving average price of $11.49. Assertio has a 52 week low of $7.65 and a 52 week high of $15.15. The stock has a market cap of $61.82 million, a PE ratio of -2.07 and a beta of 0.61. The company has a current ratio of 1.58, a quick ratio of 1.43 and a debt-to-equity ratio of 0.37.

Assertio (NASDAQ:ASRT) last posted its quarterly earnings results on Monday, November 10th. The company reported $1.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $2.85. Assertio had a negative net margin of 21.06% and a negative return on equity of 26.99%. The company had revenue of $49.46 million during the quarter, compared to the consensus estimate of $27.02 million.

Institutional Investors Weigh In On Assertio

Hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in Assertio during the 3rd quarter valued at $26,000. TSP Capital Management Group LLC raised its stake in shares of Assertio by 12.2% in the 2nd quarter. TSP Capital Management Group LLC now owns 316,875 shares of the company’s stock worth $203,000 after buying an additional 34,550 shares in the last quarter. Vanguard Group Inc. boosted its stake in Assertio by 0.9% during the third quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock valued at $3,899,000 after buying an additional 41,332 shares in the last quarter. Belpointe Asset Management LLC bought a new stake in Assertio in the first quarter worth about $65,000. Finally, Perritt Capital Management Inc grew its stake in shares of Assertio by 51.6% in the 3rd quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock worth $309,000 after purchasing an additional 119,281 shares during the last quarter. Institutional investors own 48.96% of the company’s stock.

About Assertio

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.